A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease

Evaluation of the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Phase II, Randomized, Double-blind, Placebo-controlled Clinical Study.

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of RSS0343 tablets in patients with COPD. The study includes 3 study periods: a 4-week screening period, a 48-week treatment period, and a 4-week follow-up period. The primary endpoint is the annualized rate of moderate or severe exacerbations of COPD during the 48-week treatment period.

Study Overview

• Status: Recruiting
• Conditions: Chronic Obstructive Pulmonary Disease
• Intervention / Treatment: Drug: RSS0343 tablets; Drug: RSS0343 tablets Placebo

• Study Type: Interventional
• Enrollment (Estimated): 237
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Zhou Li; Phone Number: +86 17721288193; Email: zhou.li.zl69@hengrui.com

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510140
      • Recruiting
      • First Affiliated Hospital of Guangzhou Medical University
      • Principal Investigator: Weijie Guan

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Voluntarily sign a written informed consent form.
2. Aged 40 to 80 years, male or female.
3. Body mass index (BMI) ≥18 kg/m².
4. Diagnosed with chronic obstructive pulmonary disease (COPD) as defined by the Chinese Guidelines for the Diagnosis and Management of COPD (2021 Revised Edition), with a documented COPD history of ≥12 months prior to screening.
5. Post-bronchodilator FEV₁/FVC <0.7 at the screening period; and post-bronchodilator FEV₁/FVC <0.7 with FEV₁% predicted ≥20% at baseline.
6. Documented history of at least ≥1 moderate or severe acute exacerbation of COPD (AECOPD) within 12 months prior to screening.
7. On stable doses of triple therapy or dual therapy for COPD maintenance treatment for ≥3 months prior to screening.
8. COPD Assessment Test (CAT) score ≥10 at screening and randomization.
9. Current or former smoking history of ≥10 pack-years at screening.
10. Male and female subjects of childbearing potential and their partners must have no plans for conception or sperm/ova donation for 6 months (female subjects) or 3 months (male subjects) after the last dose and must voluntarily use effective contraception. Female subjects of childbearing potential must have a negative pregnancy test during screening and prior to the first dose and must not be lactating.

Exclusion Criteria:

1. Subjects with systemic immunosuppressants, biologic agents, or Th2 cytokine inhibitors within 12 weeks prior to randomization or within 5 half-lives of the drug, whichever is longer.
2. Subjects with medications known to potentially cause skin hyperkeratosis within 4 weeks prior to screening.
3. Subjects with the followings within 4 weeks prior to randomization: systemic corticosteroids, phosphodiesterase inhibitors, xanthine derivatives, leukotriene receptor antagonists, bacterial lysates, antitussive/expectorant medications, infusion of blood products or immunoglobulins.
4. Subjects with strong CYP3A inducers or inhibitors within 14 days or 5 half-lives (whichever is longer) prior to randomization.
5. Administration of live, attenuated live, or viral vector vaccines within 4 weeks prior to randomization.
6. Participation in another clinical trial involving an investigational product with active ingredients within 3 months prior to screening, or still within 5 half-lives of the investigational product at screening.
7. Prior treatment with RSS0343 tablets or treatment with products targeting the same mechanism of action within 3 months prior to screening.
8. Lung surgery or lung volume reduction surgery within 1 year prior to screening; or interventional procedures for chronic bronchitis within 1 year prior to screening.
9. Requirement for supplemental oxygen therapy for ≥15 hours per day or mechanical ventilation; or clinically significant sleep apnea requiring the use of a continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.
10. Presence of a moderate or severe acute exacerbation of COPD (AECOPD) from 4 weeks prior to screening up to randomization.
11. Coexisting other respiratory or respiratory-related diseases.
12. Occurrence of pulmonary or other infections requiring systemic anti-infective therapy from 4 weeks prior to screening up to randomization.
13. Presence of autoimmune diseases mediated by eosinophils at screening.
14. Diagnosis of hypothyroidism, myxedema, chronic lymphedema, acromegaly, or livedo reticularis.
15. Diagnosis of psoriasis or lichen planus; Reiter's disease/keratoderma blennorrhagicum, keratoderma hemorrhagicum, or reactive arthritis; systemic lupus erythematosus, atopic dermatitis, chronic hand dermatitis, chronic contact dermatitis, or chronic psoriasis; chloracne, extensive verruca vulgaris, or keratotic dermatitis.
16. Known other severe medical conditions.
17. Laboratory tests, electrocardiogram (ECG), or other auxiliary examinations during the screening or baseline periods meeting the protocol-defined exclusion criteria.
18. Suspected or known hypersensitivity to the investigational product or any of its excipients.
19. Blood donation or blood loss ≥200 mL within 1 month prior to randomization, or ≥400 mL within 3 months prior to the first dose; or receipt of a blood transfusion within 8 weeks prior to the first dose; or difficulty with venipuncture, or physical condition unsuitable for intensive blood sampling.
20. Female subjects who are lactating, have a positive pregnancy test result, or plan to become pregnant during the study period.
21. History of drug abuse or substance abuse within 1 year prior to screening.
22. Any other medical or social reason deemed by the investigator to make the subject unsuitable for participation in the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: RSS0343 tablets	Drug: RSS0343 tablets; RSS0343 tablets
Placebo Comparator: RSS0343 tablets Placebo	Drug: RSS0343 tablets Placebo; RSS0343 tablets Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Annualized rate of moderate or severe exacerbations of COPD during the 48-week treatment period	during the 48-week treatment period

Secondary Outcome Measures

Outcome Measure	Time Frame
The time to first moderate or severe exacerbations of COPD at week 24 and 48;	at week 24 and 48;
The proportion of patients experiencing moderate or severe exacerbations of COPD at week 24 and 48	at week 24 and 48
The change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV₁) at week 4, 8, 12, 24, 36, 48, and 52	at week 4, 8, 12, 24, 36, 48, and 52
The change from baseline in pre- and post-bronchodilator forced expiratory volume in FEV₁% predicted at week 4, 8, 12, 24, 36, 48, and 52	at week 4, 8, 12, 24, 36, 48, and 52
The change from baseline in pre- and post-bronchodilator forced expiratory volume in forced vital capacity (FVC) at week 4, 8, 12, 24, 36, 48, and 52;	at week 4, 8, 12, 24, 36, 48, and 52;
The change from baseline in the COPD Assessment Test (CAT) score at week 4, 8, 12, 24, 36, 48, and 52	at week 4, 8, 12, 24, 36, 48, and 52
The change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS:COPD) score at week 4, 8, 12, 24, 36, 48, and 52	at week 4, 8, 12, 24, 36, 48, and 52
The change from baseline in the St. George's Respiratory Questionnaire (SGRQ) score at week 4, 8, 12, 24, 36, 48, and 52;	at week 4, 8, 12, 24, 36, 48, and 52;
The proportion of patients with a SGRQ response (a ≥4-point decrease from baseline) at week 48;	at week 48;
The annualized rate of moderate or severe exacerbations of COPD at week 12, 24, and 36；	at week 12, 24, and 36;

Collaborators and Investigators

• Sponsor: Reistone Biopharma Company Limited

Study record dates

Study Major Dates

• Study Start (Actual): March 10, 2026
• Primary Completion (Estimated): March 1, 2028
• Study Completion (Estimated): April 1, 2028

Study Registration Dates

• First Submitted: January 9, 2026
• First Submitted That Met QC Criteria: January 9, 2026
• First Posted (Actual): January 16, 2026

Study Record Updates

• Last Update Posted (Actual): April 17, 2026
• Last Update Submitted That Met QC Criteria: April 14, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Chronic Disease; Disease Attributes; Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pathological Conditions, Signs and Symptoms; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: RSS0343-202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No